Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.62 |
| ▸ | PTPRF | P10586 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | IKBKB | O14920 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTPRA | P18433 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14048862 | 0.89 | POLB (0.59) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL2157471 | 0.87 | MAPT (0.69) | MAPTMEN1POLBKMT2AIKBKB | |
| SCHEMBL612106 | 0.87 | PTPN1 (0.48) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL17226314 | 0.83 | PTPN1 (0.68) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL27653932 | 0.79 | PTPN1 (0.62) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL2455311 | 0.79 | PTPN1 (0.62) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL3070348 | 0.78 | IKBKB (0.82) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL14950518 | 0.77 | PTPN1 (0.45) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL14950514 | 0.77 | PTPN1 (0.45) | PTPN1PTPRFMAPTMEN1POLB | |
| SCHEMBL6317621 | 0.77 | PTPN1 (1.00) | PTPN1PTPRFMAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| WO-2008098859-A1 | HCV POLYMERASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-21 | — | — | WO | disclosed |
| WO-2007065829-A1 | ANTIVIRAL NUCLEOSIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | PTPN1 1592/4885PTPRF 364/4885MAPT 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.